Publication

Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas

Wachters, J. E., Kop, E., Slagter-Menkema, L., Mastik, M., van der Wal, J. E., Van der Vegt, B., de Bock, G. H., van der Laan, B. F. A. M. & Schuuring, E., 17-Feb-2020, In : Laryngoscope. 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Wachters, J. E., Kop, E., Slagter-Menkema, L., Mastik, M., van der Wal, J. E., Van der Vegt, B., ... Schuuring, E. (2020). Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas. Laryngoscope. https://doi.org/10.1002/lary.28532

Author

Wachters, Jan E. ; Kop, Emiel ; Slagter-Menkema, Lorian ; Mastik, Mirjam ; van der Wal, Jacqueline E. ; Van der Vegt, Bert ; de Bock, Geertruida H. ; van der Laan, Bernard F. A. M. ; Schuuring, Ed. / Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas. In: Laryngoscope. 2020.

Harvard

Wachters, JE, Kop, E, Slagter-Menkema, L, Mastik, M, van der Wal, JE, Van der Vegt, B, de Bock, GH, van der Laan, BFAM & Schuuring, E 2020, 'Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas', Laryngoscope. https://doi.org/10.1002/lary.28532

Standard

Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas. / Wachters, Jan E.; Kop, Emiel; Slagter-Menkema, Lorian; Mastik, Mirjam; van der Wal, Jacqueline E.; Van der Vegt, Bert; de Bock, Geertruida H.; van der Laan, Bernard F. A. M.; Schuuring, Ed.

In: Laryngoscope, 17.02.2020.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Wachters JE, Kop E, Slagter-Menkema L, Mastik M, van der Wal JE, Van der Vegt B et al. Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas. Laryngoscope. 2020 Feb 17. https://doi.org/10.1002/lary.28532


BibTeX

@article{2a1543cefe6046e6926a07cab5a0e5c4,
title = "Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas",
abstract = "Background In early stage laryngeal squamous cell carcinoma (LSCC) radiotherapy with curative intent is a major treatment modality. TNM classification is used to define patients eligible for radiotherapy. Studies in early stage glottic LSCC identified several predictive biomarkers associated with local control. However, we recently reported that this predictive value could not be confirmed in supraglottic LSCC.Objective To examine whether clinical behavior and protein expression patterns of these biomarkers differ between glottic and supraglottic LSCC.Study Design Retrospective cohort study.Methods Tumor tissue sections of 196 glottic and 80 supraglottic T1-T2 LSCC treated primarily with RT were assessed immunohistochemically for expression of pAKT, Ki-67 and beta-Catenin. Expression data of HIF-1 alpha, CA-IX, OPN, FADD, pFADD, Cyclin D1, Cortactin and EGFR in the same cohort of glottic and supraglottic LSCC, were retrieved from previously reported data. The relationship between glottic and supraglottic sublocalization and clinicopathological, follow-up, and immunohistochemical staining characteristics were evaluated using logistic regression and Cox regression analyses.Results Glottic LSCC were correlated with male gender (P = .001), hoarseness as a primary symptom (P <.001), T1 tumor stage (P <.001), negative lymph node status (P <.001), and an older age at presentation (P = .004). Supraglottic LSCC patients developed more post-treatment distant metastasis when adjusted for gender, age, and T-status. While supraglottic LSCC was associated with higher expression of HIF-1 alpha (P = .001), Cortactin (P <.001), EGFR (P <.001), and Ki-67 (P = .027), glottic LSCC demonstrated higher expression of CA-IX (P = .005) and Cyclin D1 (P = .001).Conclusion Differences in clinicopathological and immunohistochemical staining characteristics suggest that T1-T2 glottic and supraglottic LSCC should be considered as different entities.Level of Evidence N/A. Laryngoscope, 2020",
keywords = "Biomarkers, head and neck squamous cell carcinoma, glottic laryngeal squamous cell carcinoma, supraglottic laryngeal squamous cell carcinoma, SQUAMOUS-CELL CARCINOMA, HYPOXIA-INDUCIBLE FACTOR-1-ALPHA, LARYNGEAL CARCINOMA, CYCLIN D1, PROGNOSTIC-SIGNIFICANCE, IMMUNOHISTOCHEMICAL EXPRESSION, ACCELERATED RADIOTHERAPY, BETA-CATENIN, NECK-CANCER, E-CADHERIN",
author = "Wachters, {Jan E.} and Emiel Kop and Lorian Slagter-Menkema and Mirjam Mastik and {van der Wal}, {Jacqueline E.} and {Van der Vegt}, Bert and {de Bock}, {Geertruida H.} and {van der Laan}, {Bernard F. A. M.} and Ed Schuuring",
note = "{\circledC} 2020 The Authors. The Laryngoscope published by Wiley Periodicals, Inc. on behalf of The American Laryngological, Rhinological and Otological Society, Inc.",
year = "2020",
month = "2",
day = "17",
doi = "10.1002/lary.28532",
language = "English",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas

AU - Wachters, Jan E.

AU - Kop, Emiel

AU - Slagter-Menkema, Lorian

AU - Mastik, Mirjam

AU - van der Wal, Jacqueline E.

AU - Van der Vegt, Bert

AU - de Bock, Geertruida H.

AU - van der Laan, Bernard F. A. M.

AU - Schuuring, Ed

N1 - © 2020 The Authors. The Laryngoscope published by Wiley Periodicals, Inc. on behalf of The American Laryngological, Rhinological and Otological Society, Inc.

PY - 2020/2/17

Y1 - 2020/2/17

N2 - Background In early stage laryngeal squamous cell carcinoma (LSCC) radiotherapy with curative intent is a major treatment modality. TNM classification is used to define patients eligible for radiotherapy. Studies in early stage glottic LSCC identified several predictive biomarkers associated with local control. However, we recently reported that this predictive value could not be confirmed in supraglottic LSCC.Objective To examine whether clinical behavior and protein expression patterns of these biomarkers differ between glottic and supraglottic LSCC.Study Design Retrospective cohort study.Methods Tumor tissue sections of 196 glottic and 80 supraglottic T1-T2 LSCC treated primarily with RT were assessed immunohistochemically for expression of pAKT, Ki-67 and beta-Catenin. Expression data of HIF-1 alpha, CA-IX, OPN, FADD, pFADD, Cyclin D1, Cortactin and EGFR in the same cohort of glottic and supraglottic LSCC, were retrieved from previously reported data. The relationship between glottic and supraglottic sublocalization and clinicopathological, follow-up, and immunohistochemical staining characteristics were evaluated using logistic regression and Cox regression analyses.Results Glottic LSCC were correlated with male gender (P = .001), hoarseness as a primary symptom (P <.001), T1 tumor stage (P <.001), negative lymph node status (P <.001), and an older age at presentation (P = .004). Supraglottic LSCC patients developed more post-treatment distant metastasis when adjusted for gender, age, and T-status. While supraglottic LSCC was associated with higher expression of HIF-1 alpha (P = .001), Cortactin (P <.001), EGFR (P <.001), and Ki-67 (P = .027), glottic LSCC demonstrated higher expression of CA-IX (P = .005) and Cyclin D1 (P = .001).Conclusion Differences in clinicopathological and immunohistochemical staining characteristics suggest that T1-T2 glottic and supraglottic LSCC should be considered as different entities.Level of Evidence N/A. Laryngoscope, 2020

AB - Background In early stage laryngeal squamous cell carcinoma (LSCC) radiotherapy with curative intent is a major treatment modality. TNM classification is used to define patients eligible for radiotherapy. Studies in early stage glottic LSCC identified several predictive biomarkers associated with local control. However, we recently reported that this predictive value could not be confirmed in supraglottic LSCC.Objective To examine whether clinical behavior and protein expression patterns of these biomarkers differ between glottic and supraglottic LSCC.Study Design Retrospective cohort study.Methods Tumor tissue sections of 196 glottic and 80 supraglottic T1-T2 LSCC treated primarily with RT were assessed immunohistochemically for expression of pAKT, Ki-67 and beta-Catenin. Expression data of HIF-1 alpha, CA-IX, OPN, FADD, pFADD, Cyclin D1, Cortactin and EGFR in the same cohort of glottic and supraglottic LSCC, were retrieved from previously reported data. The relationship between glottic and supraglottic sublocalization and clinicopathological, follow-up, and immunohistochemical staining characteristics were evaluated using logistic regression and Cox regression analyses.Results Glottic LSCC were correlated with male gender (P = .001), hoarseness as a primary symptom (P <.001), T1 tumor stage (P <.001), negative lymph node status (P <.001), and an older age at presentation (P = .004). Supraglottic LSCC patients developed more post-treatment distant metastasis when adjusted for gender, age, and T-status. While supraglottic LSCC was associated with higher expression of HIF-1 alpha (P = .001), Cortactin (P <.001), EGFR (P <.001), and Ki-67 (P = .027), glottic LSCC demonstrated higher expression of CA-IX (P = .005) and Cyclin D1 (P = .001).Conclusion Differences in clinicopathological and immunohistochemical staining characteristics suggest that T1-T2 glottic and supraglottic LSCC should be considered as different entities.Level of Evidence N/A. Laryngoscope, 2020

KW - Biomarkers

KW - head and neck squamous cell carcinoma

KW - glottic laryngeal squamous cell carcinoma

KW - supraglottic laryngeal squamous cell carcinoma

KW - SQUAMOUS-CELL CARCINOMA

KW - HYPOXIA-INDUCIBLE FACTOR-1-ALPHA

KW - LARYNGEAL CARCINOMA

KW - CYCLIN D1

KW - PROGNOSTIC-SIGNIFICANCE

KW - IMMUNOHISTOCHEMICAL EXPRESSION

KW - ACCELERATED RADIOTHERAPY

KW - BETA-CATENIN

KW - NECK-CANCER

KW - E-CADHERIN

U2 - 10.1002/lary.28532

DO - 10.1002/lary.28532

M3 - Article

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

ER -

ID: 118434094